|
The Pathway for Biosimilars Act - Path or Detour? |
September 20, 2008
Previously published on September 11, 2008
With the introduction of the bipartisan Pathway for Biosimilars Act, H.R. 5629 introduced by Congresswoman Anna Eshoo (D-CA) and committee ranking member Joe Barton (R-TX), many questions have arisen as to whether this proposed legislation creates an easier path for generics to enter the biologics market, or does it simply send them on an unnecessary detour? The question must be asked, is the Act a pathway in name only?
|
The views expressed in this article are solely the views of the author and not Martindale-Hubbell. This article is intended for informational purposes only and is not legal advice or a substitute for consultation with a licensed legal professional in a particular case or circumstance. |
Practice Area Resource Centers
|
|
RSS | Blogs | Site Map | Contact Us